Markets:

Overview

News

Currencies

International

Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Sage Therapeutics: Q1 Earnings Insights ↗

May 03, 2022

Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder ↗

May 02, 2022

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 21, 2022

Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Expert Ratings For Sage Therapeutics ↗

March 31, 2022

Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:

Via Benzinga

Where Sage Therapeutics Stands With Analysts ↗

December 20, 2021

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE...

Via Benzinga

Earnings Scheduled For May 3, 2022 ↗

May 03, 2022

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

April 01, 2022

Good morning, investor! It's the last trading day of the week and that means it's time to get into the pre-market stock movers for Friday!

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022 ↗

March 31, 2022

Upgrades

Via Benzinga

Expert Ratings For Sage Therapeutics ↗

February 25, 2022

Over the past 3 months, 4 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and...

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Why A Biogen-Sage Drug Flopped — And Could Still Be Approved ↗

February 16, 2022

The companies tested a combination of zuranolone and depression drugs.

Via Investor's Business Daily

Stocks That Hit 52-Week Lows On Thursday ↗

February 17, 2022

On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...

Via Benzinga

56 Biggest Movers From Yesterday ↗

February 17, 2022

Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

February 16, 2022

Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral...

Via Benzinga

Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study ↗

February 16, 2022

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

February 16, 2022

We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

New Psychedelics ETF Launches On NYSE Arca ↗

February 02, 2022

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...

Via Benzinga

Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S. ↗

December 28, 2021

Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 27, 2021

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E...

Via Benzinga

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

5 Value Stocks To Watch In The Healthcare Sector ↗

December 06, 2021

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples...

Via Benzinga

Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients ↗

December 01, 2021

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone...

Via Benzinga

The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case ↗

December 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 08, 2021

Gainers Kiromic BioPharma (NASDAQ:KRBP) ...

Via Benzinga

What 8 Analyst Ratings Have To Say About Sage Therapeutics ↗

November 03, 2021

Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings ...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

November 03, 2021

Needham boosted Paycom Software, Inc. (NYSE:PAYC) ...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

Headline News about Sage Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today